Zotepine versus placebo for schizophrenia

  • Protocol
  • Intervention


  • Rebecca Dickenson,

    Corresponding author
    1. Nottinghamshire Healthcare NHS Trust, Community Mental Health Services, Newark, Nottinghamshire, UK
    • Rebecca Dickenson, Community Mental Health Services, Nottinghamshire Healthcare NHS Trust, 65 Northgate, Newark, Nottinghamshire, NG24 1HD, UK. rebecca.dickenson@nottshc.nhs.uk.

    Search for more papers by this author
  • Mark Fenton

    1. National Institute for Health and Clinical Excellence, Database of Uncertainties about the Effects of Treatments (DUETs), Manchester, UK
    Search for more papers by this author


This is the protocol for a review and there is no abstract. The objectives are as follows:

To review the effects of zotepine compared with placebo for people with schizophrenia or related psychoses.

As secondary objectives, we propose to investigate whether people:

  1. with schizophrenia described as 'treatment resistant' differed in their response from those whose illness was not designated as such;

  2. having predominantly positive or negative symptoms of schizophrenia were more responsive to zotepine than those without this designation; and

  3. experiencing their first episode of schizophrenia differed in their response from those at a later stage of their illness.